Inside every neuron, the lysosome is the cell's recycling center — the organelle that breaks down damaged proteins before they can accumulate and aggregate. For the proteins that cause Parkinson's disease and related synucleinopathies, alpha-synuclein¹¹ alpha-synuclein
The small protein that forms Lewy bodies — the pathological hallmark of Parkinson's disease, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), the lysosomal enzyme glucocerebrosidase (GBA)²² glucocerebrosidase (GBA)
Also called beta-glucocerebrosidase or GCase; the enzyme mutated in Gaucher disease whose reduced activity is the single largest genetic risk factor for Parkinson's disease in the general population is the primary degradation catalyst. But GBA has to get into the lysosome first — and that delivery depends on a molecular escort called SCARB2.

SCARB2 (scavenger receptor class B member 2, also known as LIMP-2) is a lysosomal membrane protein that does something no other receptor does: it grabs newly synthesized GBA in the endoplasmic reticulum and ferries it directly to the lysosome through a mannose-6-phosphate-independent trafficking pathway³³ mannose-6-phosphate-independent trafficking pathway
Most lysosomal enzymes are tagged with mannose-6-phosphate and delivered by dedicated receptors; GBA uses SCARB2 as an alternative route that is quantitatively the dominant pathway for GBA delivery. When SCARB2 function is impaired, GBA is secreted into the bloodstream rather than delivered to lysosomes — leaving the cell's recycling machinery without its main enzyme for clearing alpha-synuclein. The intronic variant rs7697073 in SCARB2, identified in the largest genome-wide association study of REM sleep behavior disorder ever conducted⁴⁴ largest genome-wide association study of REM sleep behavior disorder ever conducted
Krohn et al. Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. Nature Communications, 2022, sits at this critical molecular chokepoint.

The Mechanism

The SCARB2 protein is a 478-amino-acid type III transmembrane glycoprotein embedded in the lysosomal membrane. Its large luminal domain acts as a coiled-coil binding platform that physically docks with GBA in the ER and escort vesicles, then releases the enzyme into the acidic lysosomal lumen when the pH drops — a pH-sensitive binding and release mechanism that ensures GBA is delivered to exactly the right compartment.

Reczek et al. 2007⁵⁵ Reczek et al. 2007
Reczek et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate- independent targeting of beta-glucocerebrosidase. Cell, 2007 demonstrated that in LIMP-2-deficient cells, the majority of beta-glucocerebrosidase is secreted rather than properly localized to lysosomes, and reconstituting LIMP-2 fully rescues both enzyme delivery and lysosomal distribution. This established SCARB2/LIMP-2 as an indispensable gatekeeper of lysosomal GBA function — not a backup pathway, but the primary one.

Rothaug et al. 2014⁶⁶ Rothaug et al. 2014
Rothaug et al. LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance. PNAS, 2014 extended this to synucleinopathy biology: LIMP-2-deficient mice showed reduced GBA activity in neurons, impaired autophagy-lysosomal function, and toxic alpha-synuclein accumulation in dopaminergic neurons. Remarkably, surviving dopaminergic neurons in human Parkinson's brains showed elevated LIMP-2 levels — a compensatory upregulation that suggests the brain attempts to increase GBA delivery when alpha-synuclein load rises. Overexpressing LIMP-2 accelerated clearance of excess alpha-synuclein in the same model, pointing to SCARB2 expression as a therapeutic lever in synucleinopathy.

rs7697073 is an intronic variant that does not change the SCARB2 protein sequence, but intronic variants in regulatory-active regions can alter splicing efficiency, transcription factor binding site availability, and gene expression levels. The GWAS-identified T allele may act through reduced SCARB2 expression in brainstem or basal ganglia neurons, analogous to how the SNCA 5′ intronic RBD signals operate through altered regulatory RNA expression rather than protein coding changes.

The Evidence

The Krohn 2022 RBD GWAS⁷⁷ Krohn 2022 RBD GWAS
Krohn et al. 2022, Nature Communications enrolled 2,843 isolated RBD cases and 139,636 controls in a multi-cohort meta-analysis — the largest genetic study of RBD ever conducted. SCARB2 emerged as one of five genome-wide significant loci, together with SNCA, GBA, TMEM175, and INPP5F. The SCARB2 locus rs7697073 T allele carries an odds ratio of approximately 1.18 for RBD. A critical finding is that this RBD signal at SCARB2 is genetically independent of the PD-associated SCARB2 variant (rs6812193), meaning the SCARB2 gene harbors at least two distinct signals pointing to different aspects of its biology in different synucleinopathy subtypes.

The SCARB2-RBD connection was first established by Gan-Or et al. 2015⁸⁸ Gan-Or et al. 2015
Gan-Or et al. Parkinson's Disease Genetic Loci in Rapid Eye Movement Sleep Behavior Disorder. J Mol Neurosci, 2015, who showed that the PD-associated rs6812193 T allele (OR=0.67, p=0.004) was also protective against RBD — establishing the SCARB2-synucleinopathy connection before the 2022 GWAS had the statistical power to isolate the independent RBD signal.

Alcalay et al. 2016⁹⁹ Alcalay et al. 2016
Alcalay et al. SCARB2 variants and glucocerebrosidase activity in Parkinson's disease. NPJ Parkinson's Disease, 2016 found that despite SCARB2 rs6812193's association with PD risk (T allele OR=0.71, p=0.004), GBA enzymatic activity was similar across all genotypes — suggesting SCARB2 variants affect synucleinopathy risk through mechanisms beyond simple GBA enzyme level reduction, possibly involving lysosomal membrane organization, alpha-synuclein trafficking, or receptor-mediated signaling independent of GBA delivery.

Practical Actions

The SCARB2-GBA pathway is a target for pharmacological intervention. Ambroxol, a drug originally developed as a mucolytic, acts as a pharmacological chaperone that stabilizes GBA protein and increases its lysosomal delivery — functionally compensating for reduced SCARB2-mediated trafficking in carriers with impaired pathway function. Preclinical studies and early-phase clinical trials have demonstrated that ambroxol increases GBA activity in cerebrospinal fluid and reduces alpha-synuclein levels, making it a candidate intervention specifically for individuals with SCARB2-GBA pathway perturbations.

For T-allele carriers with RBD symptoms, specialist evaluation is the priority — RBD precedes overt synucleinopathy by a decade or more on average, and confirmed RBD opens access to prodromal cohort studies and neuroprotective trials.

Interactions

rs7697073 is genetically distinct from the PD-associated SCARB2 variant rs6812193 and operates in the same pathway as the GBA variants implicated in synucleinopathy risk. The co-identification of SCARB2 and GBA as independent RBD loci in the Krohn 2022 GWAS creates a particularly important interaction: GBA variants reduce glucocerebrosidase enzyme activity directly, while SCARB2 variants may impair GBA lysosomal delivery — both outcomes result in deficient lysosomal GBA and impaired alpha-synuclein clearance. Individuals who carry T alleles at rs7697073 (SCARB2) combined with risk variants at GBA face compounded perturbation of this same pathway from two upstream nodes simultaneously.

rs7697073 was identified in the same GWAS as the SNCA variant rs3756059 (RBD risk), the TMEM175 lysosomal channel variant rs34311866 (PD and RBD risk), and the INPP5F intronic variant rs117896735 (RBD risk). These four loci collectively highlight the autophagy-lysosomal pathway as the central biological substrate of RBD genetic risk — each gene contributing a different node in the pathway from lysosomal enzyme delivery (SCARB2) through enzymatic activity (GBA), lysosomal pH regulation (TMEM175), and membrane trafficking (INPP5F).

Your brain generates amyloid-beta peptides continuously, and healthy ageing depends on clearing them efficiently. ABCA7 — an ATP-binding cassette transporter expressed most highly in microglia and excitatory neurons — sits at the intersection of this clearance system and the brain's lipid economy. The rs78117248 variant is an intronic marker that tags an expanded VNTR¹¹ tags an expanded VNTR
Variable Number Tandem Repeat: a stretch of repeating DNA in intron 18 of ABCA7 that can expand beyond 5.6 kb, disrupting how the gene is read and the protein it produces.

The Mechanism

rs78117248 itself is a deep intronic SNP with no direct effect on protein sequence. Its significance comes from what it tracks: carriers of the G allele are significantly more likely to carry an expanded VNTR in ABCA7 intron 18²² VNTR in ABCA7 intron 18. When this repeat expands beyond roughly 5.6 kb, two things happen: overall ABCA7 expression falls (the expanded repeat recruits transcriptional repressors including ZNF263 and PLAG1), and exon 19 is skipped during mRNA splicing³³ exon 19 is skipped during mRNA splicing, removing 44 amino acids from the first nucleotide-binding domain of the protein.

The downstream effects cascade through two well-characterised pathways. First, microglia lacking functional ABCA7 cannot efficiently engulf amyloid-beta oligomers⁴⁴ cannot efficiently engulf amyloid-beta oligomers — in mouse knockouts, hippocampal amyloid clearance is substantially reduced both in cell culture and in the living brain. Second, excitatory neurons with ABCA7 loss-of-function show disrupted phosphatidylcholine metabolism, impaired mitochondrial respiration, elevated oxidative stress, and increased amyloid-beta secretion⁵⁵ disrupted phosphatidylcholine metabolism, impaired mitochondrial respiration, elevated oxidative stress, and increased amyloid-beta secretion — a constellation of changes that mirrors early-stage Alzheimer's pathology.

The Evidence

The VNTR expansion study⁶⁶ VNTR expansion study
De Roeck et al. An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. Acta Neuropathol. 2018 showed that expanded alleles were present in 7.3% of AD patients versus 1.7% of controls in a Belgian cohort (OR 4.5, 95% CI 1.3–24.2). rs78117248 was in strong LD with all three major European GWAS sentinel SNPs for ABCA7 (rs3764650, rs4147929, rs3752246).

A comprehensive 2024 review by Duchateau et al. Alzheimer's & Dementia. 2024⁷⁷ Duchateau et al. Alzheimer's & Dementia. 2024 quantified rs78117248's population-level effect at OR 1.16 (95% CI 1.11–1.20, p = 8.47 × 10⁻⁹) — a modest but robustly replicated association consistent with rs78117248 being an incomplete tag for the higher-penetrance VNTR expansion. The VNTR expansion itself explains the apparently paradoxical finding that this intronic SNP outperforms the coding GWAS variants as a statistical predictor of AD.

The most actionable recent finding comes from a 2025 Nature study by von Maydell et al.⁸⁸ von Maydell et al.: using human iPSC-derived neurons from ABCA7 loss-of-function carriers, the researchers showed that supplementing with CDP-choline (citicoline) — a precursor for phosphatidylcholine synthesis — restored choline-containing phospholipid levels, reversed mitochondrial dysfunction, reduced oxidative stress, normalised amyloid-beta secretion, and reduced neuronal hyperexcitability. This is the first mechanistically direct intervention demonstrated in human neuronal models of ABCA7 dysfunction.

Practical Actions

rs78117248 G carriers face approximately 1.15–1.20-fold elevated AD risk at the population level, with the subset who carry an expanded VNTR facing roughly 4-fold higher risk. Because the SNP tags but does not equal the functional variant, the clearest response is to support the pathways ABCA7 governs: phosphatidylcholine availability and microglial health.

CDP-choline (citicoline), sold as a cognitive supplement and studied in neurological conditions, directly feeds the phosphatidylcholine synthesis pathway that ABCA7 dysfunction impairs. Cognitive monitoring — baseline neuropsychological testing followed by regular reassessment — enables early detection of decline when interventions are most effective. Elevated homocysteine accelerates phospholipid degradation and amplifies cognitive risk; this is especially relevant in ABCA7 risk carriers given the shared neurodegeneration pathway.

Interactions

The ABCA7 locus interacts additively with APOE ε4 status: published studies confirm that ABCA7 risk variant associations remain significant after adjustment for APOE genotype, and dual carriers (ABCA7 risk + APOE ε4) show greater amyloid accumulation than either alone. The compound effect of rs78117248 (or the underlying VNTR) and APOE ε4 (rs429358) represents the strongest common-variant AD risk combination in the neurology category.

The P2X7 receptor is an ATP-gated ion channel¹¹ ATP-gated ion channel
Activated by high extracellular ATP concentrations, typically released during tissue damage, infection, or cellular stress — a "danger signal" to the immune system expressed abundantly on microglia, macrophages, and other immune cells. When extracellular ATP accumulates — as it does during inflammation, nerve injury, or cell death — P2X7 opens to admit calcium and potassium ions (channel function), and at higher ATP concentrations forms a large non-selective pore that allows molecules up to 900 daltons to enter the cell. The Arg270His variant (rs7958311, c.809G>A) sits in the extracellular ATP-binding domain and produces a cellular phenotype unlike any other common P2RX7 variant²² a cellular phenotype unlike any other common P2RX7 variant
Electrophysiology experiments across 17 P2RX7 variants found only rs7958311 showed this dual bidirectional effect: gain-of-function in channel opening combined with loss-of-function in pore formation. This split personality makes it the most clinically relevant common P2RX7 variant for chronic pain conditions.

The Mechanism

The Arg270 residue lies in the extracellular "lower body" domain of the P2X7 subunit, positioned at the interface between the ATP-binding site and the channel gate. Computational modeling using a 12-state Markov model³³ Computational modeling using a 12-state Markov model
Mathematical model of ATP binding kinetics at the P2X7 receptor explains the dual phenotype mechanistically suggests that the His270 substitution increases ATP binding affinity and open-channel conductance — making the receptor open more readily and conduct more current per opening event — while simultaneously reducing the receptor's capacity for sensitization that is required for full pore dilation. The net result is a receptor that fires more easily at low ATP concentrations (heightening sensitivity to early danger signals) but fails to fully amplify that signal to the large-pore state. In microglia — the brain's resident immune cells — this translates to enhanced responses to minor ATP release from neurons, potentially lowering the threshold for neuroinflammatory activation without reaching the full cytotoxic response associated with pore opening. This persistent low-level microglial activation, driven by the channel gain-of-function, is thought to drive central sensitization⁴⁴ central sensitization
The process by which the spinal cord and brain become hypersensitive to pain signals, amplifying and prolonging pain perception beyond the original injury — the hallmark of chronic pain disorders like fibromyalgia and IBS.

The Evidence

The most comprehensive study to date systematically characterized all 17 common nonsynonymous P2RX7 variants⁵⁵ characterized all 17 common nonsynonymous P2RX7 variants
Duke University OPPERA cohort N=3,260 plus CPPC validation cohort N=900 — the largest genetic study of P2RX7 variants and chronic pain using whole-cell patch clamp electrophysiology and genetic association analysis in the OPPERA (N=3,260) and CPPC (N=900) cohorts. Among all variants tested, rs7958311 was the only one to emerge as a significant contributor to chronic pain outcomes. The A allele was associated with increased risk of chronic pelvic pain, with convergent evidence for fibromyalgia and irritable bowel syndrome confirmed in meta-analysis. The authors concluded the unique gain-of-function/loss-of-function dual phenotype explains why this specific variant, among all common P2RX7 polymorphisms, contributes to chronic pain.

An earlier pain study using two population-based cohorts — Tromsø 6 (N=3,016) and BrePainGen (N=831)⁶⁶ Tromsø 6 (N=3,016) and BrePainGen (N=831)
Longitudinal Norwegian cohort plus breast cancer surgery patients — found the minor A allele associated with lower experimental cold-pressor pain intensity (β=−1.83 in meta-analysis, P=0.006) and lower postoperative pain. This seemingly contradictory finding (A allele = less experimental pain, but A allele = more chronic pain risk) may reflect differences between acute experimental pain (where the pore loss-of-function dominates) and chronic pain conditions (where the channel gain-of-function and persistent microglial activation are more relevant). The distinction between acute nociception and chronic pain sensitization represents distinct neurobiological processes.

Beyond pain, a case-control study of 673 ankylosing spondylitis (AS) patients and 687 controls⁷⁷ a case-control study of 673 ankylosing spondylitis (AS) patients and 687 controls
Chinese Han population study identifying sex-specific effects on AS susceptibility and disease activity found the A allele protective against AS susceptibility in females (OR=0.704, P=0.049), while paradoxically associating with higher disease activity measures in males. This sex-specific divergence aligns with known sex differences in P2X7 expression and purinergic signaling, and is consistent with the receptor's complex role in inflammation.

Practical Implications

The central clinical implication of the A allele is an elevated predisposition to chronic overlapping pain conditions — conditions where central sensitization rather than peripheral injury drives the symptoms. Fibromyalgia, chronic pelvic pain, and IBS⁸⁸ Fibromyalgia, chronic pelvic pain, and IBS
These three conditions frequently co-occur and share pathophysiology centered on central sensitization overlap substantially in their neurobiology, and all involve abnormal pain processing driven by microglial-mediated neuroinflammation. For A allele carriers, this means that after an injury or inflammatory trigger, the transition from acute to chronic pain may occur more easily than in GG carriers. Recognizing this susceptibility early allows proactive strategies: anti-inflammatory approaches to pain management, early physical therapy after injury, and close monitoring of developing chronic pain conditions.

Anti-inflammatory interventions that modulate purinergic signaling or microglial activation are particularly relevant. Omega-3 fatty acids (EPA/DHA) reduce microglial activation⁹⁹ Omega-3 fatty acids (EPA/DHA) reduce microglial activation
Multiple RCTs and observational studies show EPA/DHA reduce neuroinflammatory markers and have demonstrated efficacy in fibromyalgia. Aerobic exercise reduces central sensitization and upregulates endogenous anti-inflammatory pathways. Mind-body approaches (mindfulness-based stress reduction, CBT for chronic pain) have strong evidence for modifying central sensitization in fibromyalgia and IBS.

Interactions

Rs7958311 adds independent functional depth to the P2RX7 genetic landscape alongside the well-characterized loss-of-function Glu496Ala variant (rs3751143)¹⁰¹⁰ well-characterized loss-of-function Glu496Ala variant (rs3751143)
A near-complete loss of P2X7 receptor function reducing inflammatory signaling by 70-90%. Individuals carrying both rs7958311 A and rs3751143 C may have partially offsetting effects — the Glu496Ala dramatically reduces surface receptor expression while Arg270His alters the functional properties of receptors that are expressed. The gain-of-function variants rs208294 (His155Tyr) and rs1718119 (Ala348Thr) also interact with rs7958311 to determine net purinergic signaling tone. Additionally, P2RX7 variants interact with rs2230912¹¹¹¹ P2RX7 variants interact with rs2230912
A synonymous variant in the C-terminal domain associated with bipolar disorder and major depressive disorder in multiple studies for mood disorder susceptibility. Outside the P2RX7 gene, the NLRP3 inflammasome pathway (which P2X7 activates) and downstream IL-1β signaling represent interaction partners — variants in NLRP3, IL1B, and IL18 may modulate how the Arg270His phenotype manifests clinically.

GTP cyclohydrolase 1 (GCH1) is the rate-limiting enzyme in the synthesis of tetrahydrobiopterin (BH4)¹¹ tetrahydrobiopterin (BH4)
A critical cofactor for producing dopamine, serotonin, norepinephrine, and nitric oxide, and rs8007267 sits in the promoter region controlling its expression. This variant is one of three SNPs defining a haplotype with profound effects on pain sensitivity²² pain sensitivity
The pain-protective haplotype reduces BH4 production in response to inflammation and nerve injury, but here's the twist: whether it increases or decreases your pain depends on your ancestry.

The Mechanism

Rs8007267 lies in the 5' untranslated region (promoter) of GCH1, where it influences gene transcription. After nerve injury or inflammation, GCH1 normally ramps up production dramatically, flooding sensory neurons with BH4³³ sensory neurons with BH4
BH4 levels increase 3-5 fold in dorsal root ganglia after nerve injury. High BH4 drives excess nitric oxide production and neurotransmitter signaling, amplifying pain hypersensitivity. The variant forms of this promoter region blunt that upregulation — less GCH1 induction means less BH4 surge, which translates to reduced pain chronification⁴⁴ reduced pain chronification
Inhibiting BH4 synthesis reduces neuropathic and inflammatory pain in rodent models.

The critical detail: rs8007267 functions as part of a three-SNP haplotype (CAT: rs10483639-C, rs3783641-A, rs8007267-T). Carriers of this haplotype show reduced GCH1 mRNA upregulation⁵⁵ reduced GCH1 mRNA upregulation
Immortalized leukocytes from haplotype carriers showed decreased GCH1 induction after forskolin stimulation compared to controls when stimulated, maintaining lower BH4 levels even under inflammatory conditions.

The Evidence — and the Population Paradox

In the landmark 2006 study by Tegeder et al.⁶⁶ landmark 2006 study by Tegeder et al.
741 patients undergoing lumbar diskectomy for radicular back pain, carriers of the T allele at rs8007267 (part of the CAT haplotype) reported significantly less postoperative pain. The haplotype frequency was 15.4% in Europeans. Healthy homozygous carriers exhibited reduced experimental pain sensitivity — higher pain thresholds to mechanical stimuli. This finding has been replicated in multiple European cohorts⁷⁷ replicated in multiple European cohorts
Studies in chronic pancreatitis, postoperative pain, and experimental pain models across various pain contexts.

But in 2014, Belfer et al. discovered the opposite effect in African Americans with sickle cell disease⁸⁸ Belfer et al. discovered the opposite effect in African Americans with sickle cell disease
n=228 discovery cohort, n=513 replication cohort. The T allele was associated with MORE frequent pain crises (OR 2.23, p=0.004) and higher in vitro BH4 production. Why the flip? In European populations, T is the minor allele (~19% frequency). In African populations, T is the MAJOR allele (~32% frequency), reflecting a distinct African haplotype⁹⁹ distinct African haplotype
The African pain-risk haplotype has high BH4 production and opposite effect on endothelial function with different functional properties. The same allele, different haplotype backgrounds, opposite outcomes.

A 2018 study in African Americans with sickle cell disease¹⁰¹⁰ 2018 study in African Americans with sickle cell disease
n=131, composite pain index and acute care utilization as outcomes confirmed: each copy of the C allele (not T) was associated with 3-5 fold decrease in chronic pain scores. The direction of effect reversed compared to Europeans because the underlying haplotype structure differs by ancestry.

Practical Implications

For most people of European descent, the T allele may offer modest protection against chronic pain after injury or surgery. The effect is real but not absolute — you won't be immune to pain, but you may experience less severe or prolonged pain states. For people of African descent, especially those with conditions involving recurrent inflammatory pain (like sickle cell disease), the T allele may be a vulnerability factor.

The BH4 pathway is a therapeutic target. Inhibitors of GCH1 and downstream enzymes reduce pain in preclinical models¹¹¹¹ Inhibitors of GCH1 and downstream enzymes reduce pain in preclinical models
Sepiapterin reductase inhibitors reduce inflammatory pain without affecting basal pain sensitivity, and the existence of healthy individuals homozygous for the low-BH4 haplotype suggests substantial BH4 reduction can be tolerated. No drugs targeting this pathway are clinically available yet, but they're in development.

BH4 also regulates nitric oxide production and endothelial function¹²¹² nitric oxide production and endothelial function
GCH1 variants associated with endothelial dysfunction and oxidative stress in type 2 diabetes, linking this variant to cardiovascular health beyond pain. High BH4 can cause eNOS uncoupling, generating superoxide instead of protective nitric oxide — relevant for vascular disease risk.

Interactions

Rs8007267 forms a tight haplotype block with rs3783641 (intron 1) and rs10483639 (3' UTR)¹³¹³ haplotype block with rs3783641 (intron 1) and rs10483639 (3' UTR)
These three SNPs capture the pain-protective haplotype with 100% sensitivity and specificity. The haplotype effect is stronger than any single SNP alone. Testing all three SNPs provides the most accurate assessment of your GCH1 pain sensitivity phenotype. This would be an ideal candidate for a compound implication: individuals carrying the complete CAT haplotype (CC at rs10483639, AA at rs3783641, TT at rs8007267) have the most pronounced pain-protective effect in European populations, with approximately 2% being homozygous "double cats" who show 80% reduction in plasma BH4 after stimulation¹⁴¹⁴ 80% reduction in plasma BH4 after stimulation
Median BH4 levels in XX genotype patients reduced by 80% compared to OO patients.

There may also be interactions with other pain-related genes (COMT, OPRM1) though evidence is limited. One study found no association between GCH1 haplotype and chronic widespread pain¹⁵¹⁵ no association between GCH1 haplotype and chronic widespread pain
When tested in fibromyalgia-like conditions, the haplotype showed no effect, suggesting context-specific effects — protective for injury/inflammation-induced pain but not for centralized pain syndromes.

TRPV1 is the molecular gateway to pain in your sensory neurons, a calcium channel that opens in response to noxious heat (above 43°C), acids, and capsaicin — the compound that makes chili peppers burn. The Ile585Val variant¹¹ Ile585Val variant
rs8065080, also known as I585V or c.1191A>G, causes an amino acid substitution from isoleucine to valine at position 585 of the TRPV1 protein affects how sensitively this channel responds to pain-inducing stimuli.

TRPV1 isn't just a heat sensor. When tissue injury occurs, inflammatory mediators like bradykinin and prostaglandins sensitize TRPV1²² inflammatory mediators like bradykinin and prostaglandins sensitize TRPV1
lowering its activation threshold from ~43°C to as low as 34°C, which is why inflamed tissue hurts even at body temperature. This sensitization process is central to chronic pain conditions, making genetic variants in TRPV1 clinically meaningful beyond simple thermal sensitivity.

The Mechanism

The Ile585Val substitution sits in a critical region of the TRPV1 channel near the S4-S5 linker, an area involved in channel gating and sensitivity to vanilloid ligands like capsaicin. The isoleucine at position 585 is a hydrophobic amino acid; replacing it with valine (also hydrophobic but slightly smaller) appears to alter the channel's conformational response to activation³³ appears to alter the channel's conformational response to activation
studies suggest the Val variant may change channel morphology or stimulus-dependent gating.

Functional studies show that Val-Val carriers (GG genotype) exhibit higher capsaicin sensitivity⁴⁴ Val-Val carriers (GG genotype) exhibit higher capsaicin sensitivity
measured as lower detection thresholds for capsaicin-induced burning, while Ile-Ile carriers demonstrate reduced sensitivity to thermal pain, capsaicin, and inflammatory pain. The heterozygous state shows intermediate function, consistent with codominant inheritance.

The Evidence

The most compelling evidence comes from a meta-analysis of 8,220 individuals across seven cohorts⁵⁵ meta-analysis of 8,220 individuals across seven cohorts
Valdes et al. genotyped 3,270 symptomatic knee osteoarthritis cases, 1,098 asymptomatic OA cases, and 3,852 controls from the UK, USA, and Australia. The Ile-Ile genotype was associated with 25% lower risk of symptomatic knee OA compared to healthy controls (OR 0.75, 95% CI 0.64-0.88, p=0.00039) after adjusting for age, sex, and BMI. Crucially, no difference was seen between asymptomatic OA cases and controls, suggesting the genetic effect operates through pain perception rather than joint damage itself.

A Japanese study of 134 healthy adults⁶⁶ Japanese study of 134 healthy adults
Okamoto et al. measured burning pain thresholds using a 48°C hot plate and capsaicin sensitivity using topical application. Val-Val homozygotes showed significantly higher capsaicin sensitivity compared to Ile carriers, though associations with thermal pain were more complex, likely due to redundancy in heat-sensing mechanisms (TRPV1, TRPA1, TRPM3 all contribute).

A controlled study of 25 healthy volunteers⁷⁷ controlled study of 25 healthy volunteers
subjects with the GG genotype showed 82% less capsaicin-induced warm hypoesthesia and 22% less heat pain sensitivity gain after topical capsaicin compared to AA/AG carriers, demonstrating altered channel function under physiological conditions.

A preliminary study of 46 migraine patients⁸⁸ preliminary study of 46 migraine patients
AA genotype frequency was 61% in chronic migraine patients versus 34% in episodic migraine and 38% in controls, with complete absence of GG genotype in chronic migraine group, though a subsequent larger study and meta-analysis failed to replicate this association⁹⁹ subsequent larger study and meta-analysis failed to replicate this association
349 migraine patients showed no significant difference in rs8065080 genotype distribution.

Interestingly, a Korean diabetes study of 8,842 subjects¹⁰¹⁰ Korean diabetes study of 8,842 subjects
minor allele (Ile/A) carriers had lower HOMA-IR and reduced type 2 diabetes risk specifically when consuming high-fat diets, suggesting gene-nutrient interactions beyond pain perception.

Practical Implications

Your rs8065080 genotype influences how you experience pain from heat, inflammation, and irritating chemicals. Ile-Ile carriers (AA) experience less intense pain from these stimuli and may have higher pain tolerance, while Val-Val carriers (GG) are more sensitive and may be more prone to chronic pain conditions when tissue damage is present.

This has implications for spicy food tolerance — Val carriers genuinely experience capsaicin as more intensely burning. It may also influence susceptibility to chronic pain syndromes where TRPV1 sensitization plays a role, including inflammatory arthritis, neuropathic pain, and potentially migraine (though evidence is mixed).

For thermal injury prevention, Val carriers' higher sensitivity may offer some protective benefit by triggering withdrawal reflexes earlier. However, in chronic inflammation, this same sensitivity may amplify pain signaling and contribute to disability even when structural damage is modest.

Interactions

TRPV1 rs8065080 has been studied alongside other TRPV1 coding variants, including rs222747 (M315I) and rs222749 (P91S)¹¹¹¹ rs222747 (M315I) and rs222749 (P91S)
both also affect TRPV1 function and pain perception. While these variants show linkage disequilibrium in some populations, their combined effects on pain perception have not been systematically characterized in compound heterozygote studies.

TRPV1 functionally interacts with TRPA1 (a chemical irritant receptor)¹²¹² TRPA1 (a chemical irritant receptor)
both channels can heterodimerize and TRPA1 variants also modulate heat and capsaicin sensitivity. The combined genotype effects remain an area of active research.

Since TRPV1 is upregulated by inflammatory mediators, genetic variants affecting inflammatory pathways (COX-2, TNF-alpha signaling) may interact with TRPV1 variants to modulate chronic pain risk, though specific gene-gene interaction studies are lacking.

On chromosome 6, in the most gene-dense stretch of the human genome, sits rs9271366 — an intergenic eQTL¹¹ eQTL
An expression quantitative trait locus: a genetic variant that influences how much of a nearby gene is produced, rather than changing the protein structure itself positioned between HLA-DQA1 and HLA-DRB1. The G allele of rs9271366 tags the DR15 haplotype²² DR15 haplotype
A co-inherited block of HLA alleles: DRB1*15:01 + DQA1*01:02 + DQB1*06:02. These three genes are inherited together so frequently in European populations that detecting one tag SNP can identify the whole block, the classical HLA class II combination that is the single strongest genetic risk factor for multiple sclerosis. Together with rs3135388 (which tags DRB1*15:01 from the DRB1 side), this SNP forms a two-SNP panel for DR15 haplotype detection — capturing the DQA1 regulatory dimension that the DRB1 tag alone cannot fully resolve.

HLA-DQA1 encodes the alpha chain of the HLA-DQ class II heterodimer. This chain partners with HLA-DQB1 to form the antigen-presenting surface on dendritic cells, macrophages, and B cells — the front line of adaptive immune surveillance. The specific combination DQA1*01:02/DQB1*06:02 encoded by the DR15 haplotype creates a peptide-binding groove that, in concert with DRB1*15:01, generates an unusually permissive environment for central nervous system self-antigen presentation. Research has shown that DQA1*01:02 can form a mixed-isotype heterodimer³³ mixed-isotype heterodimer
An HLA-DQ molecule assembled from chains encoded by different classical HLA-DR and DQ loci — in this case DQA1*01:02 pairing with DRB1*15:01 — creating an antigen-presenting complex not predicted from either gene alone with DRB1*15:01, expanding the repertoire of myelin peptides that can be displayed to auto-reactive T cells beyond what each molecule presents independently.

The Mechanism

rs9271366 sits approximately 9,100 bp downstream of HLA-DQA1 and 29,200 bp upstream of HLA-DRB1, placing it in the regulatory landscape shared by both genes. As an eQTL, the G allele is associated with altered HLA class II gene expression within the DR15 haplotype block. The entire block is in strong linkage disequilibrium⁴⁴ linkage disequilibrium
Alleles that are inherited together more often than expected by chance, forming a haplotype. LD means that the G allele of rs9271366 is an excellent proxy for the presence of DRB1*15:01, DQA1*01:02, and DQB1*06:02 on the same chromosome, meaning that detecting the G allele of rs9271366 reliably indicates the presence of the full three-gene MS-risk haplotype. The DRB1 expression data from the companion SNP rs3135388 confirms that A allele carriers (who also carry the DR15 block) show 8.3-fold higher DRB1 and 15.7-fold higher DQB1 expression, flooding antigen-presenting cells with the MS-risk isoform. The rs9271366 G allele captures this same regulatory state from the DQA1 side of the haplotype.

Within the DR15 haplotype, DQA1*01:02 participates in a unique mechanistic pathway. When myelin peptides that bind well to DRB1*15:01 are exhausted or when the standard DRB1-DRA heterodimer is unavailable, the DQA1*01:02/DRB1*15:01 mixed-isotype complex can present oligodendrocyte-specific protein (OSP) epitopes to CD4+ T cells — effectively broadening the antigenic targets available to auto-reactive cells and creating backup pathways for CNS autoimmunity.

The Evidence

The MS association of rs9271366-G reached P = 7 × 10⁻¹⁸⁴ with OR approximately 2.78 in GWAS Catalog aggregated data — one of the most statistically replicated findings in human genetics. A biorepository-linked EHR study⁵⁵ biorepository-linked EHR study
Restrepo et al. analysed 28 autoimmune disease SNPs in electronic health record-linked biobank participants replicated rs9271366 as a hallmark MS SNP with OR 1.91 (p=0.008) and confirmed shared genetic architecture with rheumatoid arthritis and Crohn's disease. An Italian relapsing-remitting MS study⁶⁶ Italian relapsing-remitting MS study
Sorosina et al., 161 untreated RRMS patients with full HLA imputation from WGS found rs9271366 among five MHC loci associated with T-cell receptor diversity — carriers show expanded T-cell clonotypes, consistent with chronic autoantigen-driven T-cell expansion targeting the CNS.

The association extends across autoimmune conditions. For SLE in Hispanic/Dominican patients⁷⁷ SLE in Hispanic/Dominican patients
Liu et al., 201 SLE cases and 205 controls from the Dominican Republic, rs9271366 as a DRB1*15:01 tag SNP showed the highest SLE risk among 13 tested MHC alleles (OR=3.5, p=8.7×10⁻¹⁰). In African American women⁸⁸ African American women
Ruiz-Narvaez et al., Women's Health Study cohort, it was the most strongly associated MHC SNP for SLE (OR=1.70, p=5.6×10⁻⁵), confirming that the DR15 haplotype drives SLE risk across ancestries where this haplotype is present. In Malay and Chinese populations⁹⁹ Malay and Chinese populations
Chai et al., 790 Malaysian subjects, the G allele and GG genotype significantly increased SLE susceptibility, with a DR15-tagged haplotype (GC at rs9271366/rs9275328) reaching genome-wide significance after permutation.

The gene-environment interaction with Epstein-Barr virus documented for the companion DRB1 tag (rs3135388) applies equally here, because both SNPs tag the same haplotype. HLA-DRB1*15:01 acts as a co-receptor for EBV infection of B cells¹⁰¹⁰ HLA-DRB1*15:01 acts as a co-receptor for EBV infection of B cells
Sundqvist et al., demonstrating the mechanistic link between the two strongest known MS risk factors. G allele carriers have more DR15 co-receptor surface available for viral entry, potentially sustaining higher EBV loads, more robust EBNA-1 antibody responses, and higher rates of molecular mimicry against myelin antigens.

Practical Implications

rs9271366 provides complementary information to rs3135388: both tag the DR15 haplotype, but from different positions flanking the DQA1/DRB1 locus. When both SNPs are available (as with WGS or comprehensive genotyping arrays), concordant G-at-rs9271366 and A-at-rs3135388 readings provide higher-confidence DR15 identification than either alone. When only one is available, each serves as a reliable proxy with >95% sensitivity.

The practical actions are shared with the DRB1 tag: vitamin D optimization to dampen the VDRE-driven upregulation of the DR15 allele, and vigilance for early MS symptoms. The vitamin D response element (VDRE) in the HLA-DRB1*15:01 promoter means that vitamin D insufficiency may directly increase expression of the MS-risk isoform in G allele carriers; maintaining serum 25(OH)D above 40 ng/mL is the most evidence-backed modifiable intervention for this haplotype. Approximately 25–30% of Europeans carry at least one DR15 chromosome, but lifetime MS risk remains approximately 1–3% for heterozygotes — HLA is necessary but not sufficient.

Interactions

rs9271366 and rs3135388 are in strong LD and tag the same DR15 haplotype from flanking positions. They are partner SNPs in the GeneOps dual-panel for DR15 detection: concordant results provide the highest confidence, while discordance may reflect genotyping error or, rarely, a partial haplotype. The DQA1*01:02/DRB1*15:01 mixed-isotype heterodimer effect is relevant specifically to rs9271366 as the DQA1-proximal tag: it captures the DQA1*01:02 allele that forms this cross-isotype antigen-presenting complex. Interactions with rs2187668 (HLA-DQ2.5 tag for celiac/T1D) and rs7454108 (HLA-DQ8 tag for T1D) concern distinct haplotype blocks and are not additive for MS risk. The IBD association of rs9271366 reflects a different alternate allele (C) tagging DRB1*15:02, which is unrelated to the G allele DR15 MS-risk signal analyzed here.

On chromosome 6, tucked in the intergenic stretch between HLA-DQB1 and HLA-DQA2 at position 32,699,045 (GRCh38), sits rs9275328 — the third pillar of the DR15 haplotype tag panel. Its C allele marks the presence of DQB1*06:02¹¹ DQB1*06:02
The HLA-DQ beta-1 chain allele that completes the DR15 haplotype: DRB1*15:01 + DQA1*01:02 + DQB1*06:02. These three genes are so tightly co-inherited across populations that a single SNP in each flanking region can identify the whole haplotype block with high accuracy, the allele that encodes the DQ beta chain partnering with DQA1*01:02 to form the most strongly MS-associated HLA-DQ heterodimer known. Together with rs3135388 (DRB1 side) and rs9271366 (DQA1 side), this SNP closes a three-locus surveillance net: when all three risk alleles are present, the DR15 haplotype is identified with the highest possible confidence from standard genotyping data.

HLA-DQB1 encodes the beta chain of the HLA-DQ class II antigen-presenting molecule. The beta chain forms the floor and one wall of the peptide-binding groove, and DQB1*06:02 creates a groove geometry that, in combination with the DQA1*01:02 alpha chain, is uniquely permissive for presenting myelin and oligodendrocyte peptides to auto-reactive CD4+ T cells. This same DQA1*01:02/DQB1*06:02 combination also drives narcolepsy risk through a distinct mechanism: it presents hypocretin-neuron-derived peptides that, after molecular mimicry triggered by viral infection or vaccination, are targeted by cytotoxic immune responses that destroy the hypothalamic hypocretin-producing neurons responsible for wakefulness regulation.

The Mechanism

rs9275328 sits approximately 31 kb downstream of the HLA-DQB1 gene body (GRCh38 gene end ~32,668,383; SNP at 32,699,045) and approximately 2 kb upstream of HLA-DQA2. Like rs9271366, it functions as a haplotype tag in strong linkage disequilibrium²² linkage disequilibrium
LD with D'=0.941 between rs9271366 and rs9275328 (Chai et al. 2013), meaning the two alleles are almost always inherited together; r²=0.065 indicates they are not perfectly correlated but the haplotype GC tags a consistent biological state with the DQB1*06:02 allele across the DR15 haplotype block.

The C allele of rs9275328 is the DR15 haplotype allele. The T allele marks non-DR15 chromosomes and, when present as a heterozygote (CT), breaks up the homozygous DR15 state — which is why the CT genotype itself showed a protective OR in the Chai SLE cohort. The high DQB1 expression³³ high DQB1 expression
15.7-fold higher DQB1 expression in DR15 haplotype carriers documented in the rs3135388 eQTL study applies here too: the C allele at rs9275328 co-segregates with all the regulatory machinery driving elevated DRB1*15:01, DRB5*01:01, and DQB1*06:02 expression. The DQB1*06:02 beta chain is expressed on all antigen-presenting cell surfaces in CC homozygotes, dramatically increasing the capacity for DR15-type self-antigen presentation in the thymus and periphery.

The Evidence

The SLE evidence is direct. Chai et al. 2013⁴⁴ Chai et al. 2013
360 Malaysian SLE patients vs 430 healthy controls across Malay, Chinese, and Indian ethnicities; TaqMan genotyping of both rs9275328 and rs9271366 found that the C allele and CC genotype at rs9275328 increased SLE susceptibility in Malays and Chinese (OR > 1, p < 0.05), while the minor T allele and CT heterozygotes were protective (OR < 1, p < 0.05). The haplotype GC (rs9271366-G / rs9275328-C) reached genome-wide significance after 10,000 permutation tests. Multifactor dimensionality reduction testing identified the GG/CC and AG/CC genotype combinations as the high-risk class, directly implicating rs9275328-CC as a required component of the highest-risk SLE genotype.

For MS, the DQB1*06:02 allele that rs9275328-C tags has well-established independent risk contribution. Fine-mapping the MHC in MS⁵⁵ Fine-mapping the MHC in MS
International MHC fine-mapping studies across thousands of patients established that the full DR15 haplotype (DRB1*15:01/DQA1*01:02/DQB1*06:02) drives MS risk, with heterozygous DR15 carriers at OR approximately 2.1–2.8 and homozygotes at OR approximately 4–6 compared to non-carriers. The DQB1*06:02 beta chain forms the antigen-presenting surface that displays myelin peptides⁶⁶ antigen-presenting surface that displays myelin peptides
Including MBP, MOG, and OSP peptides that are targets of auto-reactive CD4+ T cells in MS — a function independent of DRB1*15:01 that explains why DQB1*06:02 adds to MS risk beyond the DRB1 contribution alone.

Narcolepsy adds a third condition to this SNP's profile. A systematic meta-analysis across four ethnic groups⁷⁷ A systematic meta-analysis across four ethnic groups
Liblau et al. 2018, 30,000+ subjects found HLA-DQB1*06:02 confers an odds ratio of 24.1 (CI 14.6–39.5) for narcolepsy type 1 — one of the largest genetic effect sizes recorded for any common variant. Over 90% of narcolepsy with cataplexy patients in European and East Asian populations carry at least one copy of DQB1*06:02, compared to 15–25% of controls. rs9275328-C, as a tag for this allele, captures this extraordinary narcolepsy susceptibility signal.

Practical Implications

rs9275328-C completes the three-SNP DR15 panel alongside rs3135388 and rs9271366. When all three risk alleles are concordant (A at rs3135388, G at rs9271366, C at rs9275328), DR15 haplotype identification is near-certain from standard genotyping data. For CC homozygotes with both other DR15 tags also homozygous, the combined evidence represents the highest HLA-based MS and narcolepsy genetic risk configuration captured by this platform.

The modifiable intervention is the same as for the other two DR15 tags: vitamin D optimization. The vitamin D response element in the DRB1*15:01 promoter⁸⁸ vitamin D response element in the DRB1*15:01 promoter
Ramagopalan et al. 2009 — the VDR binding site in the DRB1*15:01 promoter means vitamin D directly regulates expression of the MS-risk allele operates across the whole haplotype block, and DQB1*06:02 expression co-varies with DRB1*15:01 regulation. Vitamin D insufficiency may amplify DR15 allele expression; maintaining serum 25(OH)D above 40 ng/mL is the primary evidence-backed modifiable lever.

For narcolepsy, the key practical implication is recognising excessive daytime sleepiness combined with sudden muscle weakness triggered by strong emotions (cataplexy) as a specific clinical pattern warranting hypocretin/orexin testing. Early diagnosis enables treatment with sodium oxybate or pitolisant that dramatically improves quality of life.

Interactions

rs9275328 is the DQB1-side tag for the same DR15 haplotype block tagged by rs3135388 (DRB1 side) and rs9271366 (DQA1 side). In the Chai SLE study, the haplotype GC (rs9271366-G + rs9275328-C) and the MDR high-risk combination GG/CC (rs9271366/rs9275328) demonstrated multiplicative interaction: homozygous DR15 at both loci produced the highest SLE risk class. The DR15 haplotype block has D'=0.941 between rs9271366 and rs9275328, indicating very strong but not perfect LD — meaning the two SNPs occasionally separate on different chromosomes, and concordant genotyping across all three tag SNPs reduces false positive/negative haplotype calls. The narcolepsy risk from DQB1*06:02 is partially separable from the MS risk of the full DR15 haplotype: DQA1*01:02 is required as co-receptor partner for narcolepsy, making the DQA1/DQB1 pair (captured by rs9271366 + rs9275328) the most proximal genetic risk unit for narcolepsy type 1.

Every human's capacity for learning sits at the intersection of genetics and experience. Among the thousands of common variants that nudge cognitive development, one stands apart for reproducibility: rs9320913, a regulatory variant upstream of POU3F2¹¹ POU3F2
also called BRN-2 (Brain-2); a POU-domain transcription factor essential for the differentiation of cortical neurons and the generation of upper-layer neocortical neurons on chromosome 6. First identified as the lead GWAS hit for educational attainment in Rietveld et al. 2013²² Rietveld et al. 2013
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science 340:1467–1471, rs9320913 has replicated in every large-scale follow-up, including the million-person Lee et al. 2018 study. The A allele at this locus is associated with approximately one month less schooling per copy — a small effect per variant, but the effect is among the most reliably detected cognitive GWAS signals in human genetics.

The Mechanism

rs9320913 sits in an intergenic region upstream of POU3F2, where it is thought to influence gene expression in fetal and adult brain tissue. POU3F2 encodes a transcription factor³³ transcription factor
a protein that binds DNA and controls which genes are switched on or off in a cell; POU3F2 is a master regulator of neuronal identity programs that is indispensable for cortical neuron differentiation. It governs the transition from direct to indirect neurogenesis — the cellular process that expands the neocortex and generates the upper-layer neurons responsible for higher cognition — and remains expressed in the adult brain, where it supports ongoing hippocampal neurogenesis and working memory.

POU3F2 regulates downstream genes involved in synaptic connectivity, including members of the neurexin family. Neurexins (including NRXN1) are synaptic cell-adhesion molecules that organise NMDA receptor scaffolding; disrupted neurexin expression alters NMDA receptor⁴⁴ NMDA receptor
N-methyl-D-aspartate receptor; the glutamate receptor subtype central to long-term potentiation (LTP) and the molecular basis of memory formation function and synaptic plasticity. This pathway — POU3F2 → neurexin signalling → NMDA receptor function → LTP — is one mechanistic bridge between the rs9320913 regulatory locus and variation in cognitive performance.

The Evidence

The foundational study is Rietveld et al. 2013⁵⁵ Rietveld et al. 2013
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science 340:1467–1471, which identified rs9320913 as one of three genome-wide significant SNPs for years of schooling (P < 5×10⁻⁸). The effect size — approximately 0.10 standard deviations, or about one month of schooling per A allele — appears small, but this is expected for a highly polygenic trait. In Lee et al. 2018⁶⁶ Lee et al. 2018
Gene discovery and polygenic prediction from a GWAS of educational attainment in 1.1 million individuals. Nature Genetics 50:1112–1121, which extended the analysis to 1.1 million participants, 1,271 independent genome-wide significant SNPs were discovered and polygenic scores based on all common variants now explain 11–13% of the variance in educational attainment — a substantial fraction for any complex behavioural trait. The locus has also been replicated in the intermediate Okbay et al. 2016⁷⁷ Okbay et al. 2016
Genome-wide association study identifies 74 loci associated with educational attainment. Nature 533:539–542 study (N=293,723).

The biological plausibility is supported by mouse models. Hashizume et al. 2018⁸⁸ Hashizume et al. 2018
POU3F2 participates in cognitive function and adult hippocampal neurogenesis via mammalian-characteristic amino acid repeats. Genes Brain Behav demonstrated that mice with disrupted POU3F2 function show impaired object recognition memory and spatial memory, and reduced production of new neurons in the adult hippocampus — directly implicating POU3F2 in postnatal learning and memory circuits. Notaras et al. 2022⁹⁹ Notaras et al. 2022
Schizophrenia is defined by cell-specific neuropathology. Molecular Psychiatry 27:1416–1434 showed that BRN2 (POU3F2) is severely depleted in schizophrenia-derived neural progenitors, and lentiviral BRN2 rescue restores neuron production — establishing BRN2 as non-redundant for neuronal differentiation in human brain tissue.

Practical Actions

The A allele's effect operates through a neurodevelopmental pathway involving NMDA receptor function. The NMDA receptor requires three co-factors for full activation: glutamate (its primary agonist), glycine or D-serine (obligatory co-agonist at the GluN1 subunit), and magnesium (voltage-dependent channel blocker that sets the activation threshold). Magnesium L-threonate crosses the blood-brain barrier more efficiently than other magnesium salts and has been shown in a placebo-controlled RCT to improve executive function in adults with cognitive complaints (Liu et al. 2016¹⁰¹⁰ Liu et al. 2016
Efficacy and Safety of MMFS-01 for Treating Cognitive Impairment in Older Adults. J Alzheimer's Disease 48:353–364). Glycine, as an obligatory NMDA co-agonist, is reliably present in adequate dietary amounts for most people, but targeted glycine supplementation has been studied for cognitive enhancement in contexts where NMDA hypofunction is suspected. Zinc is an endogenous NMDA modulator that gates channel conductance and has bidirectional effects depending on concentration.

For CC individuals: no specific intervention is indicated at this locus. The POU3F2 regulatory region is functioning in the population-typical range.

Interactions

rs9320913 is one of three early landmark SNPs for educational attainment (rs11584700 near NRXN1 and rs4851266 near KCTD13 were the others identified in Rietveld 2013). NRXN1 is a neurexin directly involved in NMDA receptor scaffolding, making rs11584700 a pathway partner: both SNPs converge on synaptic plasticity and NMDA function, though via different molecular nodes. The Lee et al. 2018 polygenic score, which aggregates effects from 1,271 loci, substantially outperforms any individual SNP for prediction — the real clinical utility of rs9320913 lies not in isolation but as one of the most reliably anchored landmarks in the educational attainment genetic architecture.

A single nucleotide variant sitting in an intron of the PHACTR1 gene on chromosome 6 has one of the most remarkable genetic profiles in cardiovascular and neurological medicine: its two alleles pull risk in opposite directions across five vascular diseases. Carry the A allele and you are predisposed to migraine headaches, cervical artery dissection, and fibromuscular dysplasia. Carry the G allele and your migraine risk falls — but your risk of coronary artery disease and myocardial infarction rises. The same switch, flipped in opposite directions for two different arteries, illustrates why the PHACTR1 locus has attracted intense interest from both neurologists and cardiologists.

PHACTR1¹¹ PHACTR1
phosphatase and actin regulator 1 — a protein involved in cytoskeletal regulation, vascular compliance, and endothelial gene expression is expressed predominantly in endothelial and vascular smooth muscle cells. The rs9349379 variant lies in a large intron (between exons 5 and 6) but is not silent — it sits in a regulatory enhancer active in aortic tissue and alters the binding of myocyte enhancer factor-2 (MEF2) transcription factors to that enhancer.

The Mechanism

The molecular story has two layers. First, rs9349379 affects PHACTR1's own expression: the G allele disrupts MEF2 binding, reducing PHACTR1 transcription in human coronary arteries and aorta. Wang & Musunuru 2018²² Wang & Musunuru 2018
Circulation Genomic Precision Med confirmed this using CRISPR-edited iPSC-derived endothelial cells with knock-in of each allele — GG homozygotes expressed less PHACTR1 than AA homozygotes.

Second, and more dramatically, rs9349379 acts as a distal enhancer for endothelin-1 (EDN1), located 600 kb upstream of PHACTR1. Gupta et al. 2017³³ Gupta et al. 2017
Cell used CRISPR deletion of the 88-bp regulatory element at rs9349379 in iPSC-derived endothelial cells and vascular smooth muscle cells; deletion increased EDN1 expression, and analysis of 99 healthy individuals confirmed that each G allele raises Big ET-1 plasma levels. Endothelin-1 is a potent vasoconstrictor that also promotes vascular smooth muscle proliferation, extracellular matrix deposition, and arterial fibrosis — effects consistent with coronary plaque vulnerability.

The opposing disease profiles arise because atherosclerotic coronary artery disease (plaque-dependent) and migraine with aura (vasospasm and cortical spreading depression) represent fundamentally different vascular failure modes. Higher ET-1 from the G allele promotes the chronic endothelial injury model of atherosclerosis while the A allele's arterial-wall compliance changes (fibromuscular dysplasia, CeAD) reflect a structural fragility model distinct from plaque. PHACTR1 itself, when reduced by the G allele, may also modulate endothelial inflammation via NF-κB-dependent ICAM-1/VCAM-1 expression.

The Evidence

Hautakangas et al. 2022⁴⁴ Hautakangas et al. 2022
Nature Genetics — the largest migraine GWAS to date (102,084 cases, 771,257 controls) — identified rs9349379 as the sole credible causal variant at the PHACTR1 locus with a posterior inclusion probability of 1.00. The association reached P ≈ 1×10⁻⁴⁷, placing it among the top migraine loci genome-wide. PHACTR1 was one of only two genes prioritized with strong evidence by both gene prioritization methods used in the study. The association held for migraine both with and without aura.

The pleiotropy was formally quantified by Winsvold et al. 2017⁵⁵ Winsvold et al. 2017
PLOS ONE using conjunctional FDR analysis across 23,285 migraine cases and multiple CAD cohorts: the A allele showed beta = +0.073 for migraine (P = 6.4×10⁻⁸) but beta = −0.159 for CAD (P = 6.5×10⁻²¹) — opposite signs, both highly significant.

For cervical artery dissection, Debette et al. 2015⁶⁶ Debette et al. 2015
Nature Genetics found the G allele protective (OR = 0.75, P = 4.5×10⁻¹⁰, 2,052 cases/17,064 controls). For fibromuscular dysplasia, Kiando et al. 2016⁷⁷ Kiando et al. 2016
PLoS Genetics found the A allele confers OR = 1.39 (P = 7.4×10⁻¹⁰, 1,154 FMD cases). The A allele is rare in Africans (~8%) but common in East Asians (~32% homozygous AA), producing dramatically different population-level vascular disease burdens.

Practical Actions

For carriers of the AA genotype (two A alleles): migraine susceptibility is elevated, and while the vascular mechanism is distinct from classical atherosclerosis, the endothelial and arterial-wall changes associated with the A allele also raise risk of cervical artery dissection and fibromuscular dysplasia. Vasoconstrictive migraine treatments (ergotamine, dihydroergotamine) carry theoretical concern in individuals already predisposed to arterial wall pathology, and triptans — which carry black-box warnings for coronary vasospasm — are worth discussing with a neurologist who knows this genotype.

For GG carriers: migraine risk is low, but the G allele's higher ET-1 production and reduced PHACTR1 expression increase coronary artery disease risk independently of traditional risk factors. Standard cardiovascular risk management is therefore especially important.

Interactions

The PHACTR1 locus interacts at the pathway level with other vascular endothelial variants. The EDN1 pathway is shared with rs5370 (EDN1 Lys198Asn), which directly alters the endothelin-1 peptide sequence and affects vasoconstrictor tone. Variants in EDNRA and EDNRB (endothelin receptor genes) could compound the rs9349379 regulatory effect on ET-1 signalling. NOS3 variants (e.g., rs1799983 ENOS Glu298Asp) affecting nitric oxide production operate antagonistically to endothelin-1 in vascular tone regulation; a combined PHACTR1-AA / NOS3-risk genotype may produce additive vascular wall dysfunction. These pathway interactions are candidates for compound actions but require published evidence of combined effects before they can be formally modelled.